RYTM - Rhythm Pharma gains after Ladenburg upgraded on potential of weight loss therapy

Rhythm Pharmaceuticals (RYTM +12.1%) has recorded the biggest intraday gain since November 2020 after Ladenburg Thalmann upgraded the commercial-stage biopharmaceutical company to Buy from Neutral. The firm highlighted the prospects of Imcivree, an FDA-approved therapy marketed by the company for chronic weight management in adults and children with obesity due to certain deficiencies. Noting that Rhythm (NASDAQ:RYTM) shares have lost more than 77% over the past 12 months, underperforming the Nasdaq Biotechnology Index, the analysts expect the company shares to recover with label expansion for Imcivree in BBS. In September, Rhythm (RYTM) announced the completion of its supplemental New Drug Application ((sNDA)) to the FDA for approval of Imcivree to treat obesity and control of hunger in those with BBS or Alström syndrome. Even as "the limited clinical trial evidence in 2022 continues to” impact the outlook, the firm notes that the company is trading at a market cap comparable

For further details see:

Rhythm Pharma gains after Ladenburg upgraded on potential of weight loss therapy